Glycosylated haemoglobin (HbA1c) - A marker of circulating lipids in type 2 diabetic patients

Journal of Clinical and Diagnostic Research

Volumn 8, Issue 2, 2014, Pages 20-23

  Prabhavathi, K ^a   Kirthana Kunikullaya, U ^b   Goturu, Jaisri ^b  

^a SRM INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

^b M S RAMAIAH MEDICAL COLLEGE   (India)

Author keywords

Coronary artery disease; Dyslipidemia; Glycemic control

Indexed keywords

ANTILIPEMIC AGENT; BIOCHEMICAL MARKER; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; RISK FACTOR; SEX;

EID: 84893503976     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2014/7742.3996     Document Type: Article

References (37)

1. Bulatao RA, Stephens PW. Global estimates and projections of mortality by cause. Washington DC: Population, Health and nutrition Department; World Bank; pre-working paper 1007, 1992.
2. Enas EA, Jacob S. Coronary artery disease in Indians in the USA. In: Sethi K, ed. Coronary artery disease in Indians-A Global Perspective. Mumbai. Cardiological Society of India. 1998:32-43.
3. Ader DJ. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med. 2007;120(3 Suppl 1):S12-8.
4. 1c as a marker of circulating lipids in male and female type 2 diabetic patients. Acta Diabetol. 2007; 44:193-200.
5. Giansanti R, Rabini RA, Romagnoli F, Fumelli D, Sorichetti P, Boemi M, et al. Coronary heart disease, type 2 diabetes mellitus and cardiovascular disease risk factors: a study on a middle-aged and elderly population. Arch Genontol Geriatr. 1999; 29(2):175-82.
6. Ravipati G, Aronow WS, Ahn C, Sujata K, Saulle LN, Weiss MB. Association of hemoglobin A(1c) level with the severity of ischemic heart disease in patients with diabetes mellitus. Am J Cardiol. 2006;97(7):968-9.
7. America Diabetes Association. Standards of medical care in diabetes. Diabetes care. 2004;27(Suppl 1): S15-S35.
8. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of Coronary Heart Disease Using Risk Factor Categories. Circulation. 1998;97(18):1837-47.
9. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351-64.
10. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237-45.
11. Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care. 1990;13(2):153-69.
12. Jones PH. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus. Am J Cardiol. 2007;99(4A):133B-140B.
13. Warnick GR, Knopp RH, Fitzpatrick V, Branson L. Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem. 1990;36(1):15-9.
14. Rosediani M, Azidah AK, Mafauzy M. Correlation between fasting plasma glucose, post prandial glucose and glycated haemoglobin and fructosamine. Med J Malaysia. 2006;61(1):67-71.
15. DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the diabetes control and complications trial. Diabetes. 1996;45(10):1289-98.
16. Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med. 2005;165(16):1910-16.
17. Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F, et al. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment and geographic location. Diabetes Care. 2007;30(5):1241-7.
18. Smellie WS. Hypertriglyceridaemia in diabetes. BMJ. 2006;333(7581):1257-60.
19. Ladeia AM, Adan L, Couto-Silva AC, Hiltner A, Guimaraes AC. Lipid profile correlates with glycemic control in young patients with type 1 diabetes mellitus. Prev Cardiol. 2006;9(2):82-8.
20. Chan WB, Tong PC, Chow CC, So WY, Ng MC, Ma RC, et al. Triglyceride predicts cardiovascular mortality and its relationship with glycemia and obesity in Chinese type 2 diabetic patients. Diabetes Metab Res Rev. 2005;21(2):183-8
21. Huang ES, Meigs JB, Singer DE. The effect of interventions to prevent cardiovascular diseases in patients with type-2 diabetes mellitus. Am J Med. 2001;111(8):633-42.
22. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. Risk Factors for myocardial infarction and death in newly detected NIDDM: the Diabetes intervention study, 11-year follow-up. Diabetologia. 1996;39(12):1577-83.
23. 1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J. 2006;151(1):91.
24. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res. 1996;37(4):693-707.
25. Kalofoutis C, Piperi C, Zisaki A, Singh J, Harris F, Phoenix D, et al. Differences in expression of cardiovascular risk factors among type 2 diabetes mellitus patients of different age. Ann N Y Acad Sci. 2006;1084:166-77.
26. Petitti DB, Imperatore G, Palla SL, Daniels SR, Dolan LM, Kershnar AK, et al. Serum lipids and glucose control: the SEARCH for Diabetes in Youth study. Arch Pediatr Adolesc Med. 2007;161(2):159-65.
27. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229-34.
28. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281(14):1291-7.
29. Esteghamati A, Abbasi M, Nakhjavani M, Yousefizadeh A, Basa AP, Afshar H. Prevalence of diabetes and other cardiovascular risk factors in an Iranian population with acute coronary syndrome. Cardiovasc Diabetol. 2006;5:15.
30. Sibley SD, Thomas W, de Boer I, Brunzell JD, Steffes MW. Gender and elevated albumin excretion in the Diabetes Control and Complications trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort: role of central obesity. Am J Kidney Dis. 2006;47(2):223-32.
31. Nasri H, Yazdani M. The relationship between serum LDL-cholesterol, HDL-cholesterol and systolic blood pressure in patients with type 2 diabetes. Kardiol Pol. 2006;64(12):1364-8; discussion. 1369-71.
32. Nasri H, Yazdani M. The relationship between serum LDL-cholesterol, HDL-cholesterol and systolic blood pressure in patients with type 2 diabetes. Kardiol Pol. 2006;64(12):1364-8; discussion 1369-71.
33. Arora M, Koley S, Gupta S, Sandhu JS. A Study on Lipid Profile and Body Fat in Patients with Diabetes Mellitus. Anthropologist. 2007;9(4):295-8.
34. Taylor KG, John WC, Mathews KA, Wright AD. A prospective study on the effect of 12 months treatment on serum lipids and apolipoproteins A-I, A-II and B in type II (non insulin dependent). Diabetologia. 1982;23(6):507-10.
35. Witztum JL, Mahoney EM, Branks MJ, Fisher M, Elam R, Steinberg D. Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity. Diabetes. 1982;31(4 Pt 1):283-91.
36. Kissebah AH, Alfarsi S, Evans DJ, Adams PW. Integrated regulation of very low-density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes. 1982;31(3):217-25.
37. Tangvarasittichai S, Poonsub P, Tangvarasittichai O. Association of serum lipoprotein ratios with insulin resistance in type 2 diabetes mellitus. Indian J Med Res. 2010;131:641-8.